FDA Approves MedImmune's Refrigerated Formulation of FluMist
The FDA has approved MedImmune's (Gaithersburg, MD, www.medimmune.com) new refrigerated formulation of FluMist (influenza virus vaccine live, intranasal), which is used to help prevent influenza in healthy children and adults from 5 to 49 years of age.
The FDA has approved MedImmune’s (Gaithersburg, MD, www.medimmune.com) new refrigerated formulation of FluMist (influenza virus vaccine live, intranasal), which is used to help prevent influenza in healthy children and adults from 5 to 49 years of age.
FluMist has been marketed in a frozen formulation since its original FDA approval in 2003, and millions of doses have been distributed and administered. The newly approved formulation of FluMist, known in clinical studies as CAIV-T (cold adapted influenza vaccine-trivalent), will be available for the 2007–2008 influenza season. Both formulations are free of preservatives, including thimerosal.
Pending the FDA's approval of an expanded age indication, MedImmune plans to increase production of its new formulation of FluMist for the 2007–2008 season. The company anticipates shipping its first doses in 2007, in time for physicians to start vaccinating patients as early as August.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
The Role of On-Demand Manufacturing and Derisking in Accelerating Early Clinical Trial Success
June 4th 2025Small pharmaceutical companies are constantly seeking innovative solutions to streamline early clinical trials. Adaptive clinical trials offer important benefits to sponsors and patients, both from a commercial and ethical standpoint. These trials offer flexibility and efficiency, especially in the early stages, where trial protocols can be adjusted based on interim data, such as introducing new doses or modifying participant sample size. However, adjusting manufacturing demand during an adaptive trial can be complicated, and strict regulatory requirements present significant challenges. On-demand manufacturing provides a robust solution, allowing for real-time supply and demand adjustments and improved trial flexibility. This paper explores how on-demand manufacturing meets the operational needs of adaptive trials and aligns with regulatory expectations.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
